What’s Next for Sangamo After This Hemophilia Study
Sangamo Therapeutics shares jumped on Tuesday after the company announced interim data from its midstage hemophilia trial in collaboration with Pfizer.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 104
How Apyx Medical Was Crushed by the FDA
Apyx Medical shares dropped sharply on Tuesday after the company announced that it has voluntarily withdrawn its application for premarket notification 510(k) regulatory clearance of J-Plasma/Renuvion for use in dermal resurfacing procedures.
Americans Borrowed $88 Billion for Health Care Last Year
Health care costs in the United States are generally measured as the highest in the world. Last year, many Americans could not afford their health care costs.
What’s Next for Tricida’s Chronic Kidney Disease Treatment
Tricida shares jumped on Thursday after the firm announced results from its chronic kidney disease study.
Can Proteon Therapeutics Come Back From This Chronic Kidney Disease Study?
Proteon Therapeutics shares were absolutely crushed on Thursday after the firm announced results from its late-stage trial in patients with chronic kidney disease.
Why Pfizer May Soon Make Up Lost Ground in Underperforming Against Merck
According to Credit Suisse, Pfizer investors might be getting to make up some of that relative underperformance of late.
Why the Market Is Punishing Centene Over Its Planned WellCare Health Plans Acquisition
This is one of those mergers that is not getting the warm fuzzy feeling that management teams love to see.
What’s Next for Axsome Therapeutics After This FDA Approval
Axsome shares jumped on Wednesday after the firm gave an update from the FDA regarding its AXS-05 for the treatment of major depressive disorder.
Major Pharma Sees a Few Wild Swings in Short Interest
The March 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased, with two major movers in the group.
Big Biotechs Scare Off Short Sellers
The March 15 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
Why Is Purdue Settling Oklahoma Opioid Lawsuit for $275 Million?
Tuesday afternoon, the attorney general of Oklahoma is expected to announce that the state has reached a settlement with Purdue Pharma that will see the state receive a $275 million payout from the company.
Will Pacemakers and Other Medical Implants Be Hacked?
The U.S. FDA has proposed new guidelines to address cybersecurity threats to implanted medical devices. Comments on the guidelines are split along lines of healthcare providers and medical device makers.
Why Curis Shares Are Booming
Curis shares jumped when the firm announced that it entered into an agreement to sell rights to a portion of royalty revenues on worldwide net sales of Erivedge.
Picking Up the Pieces: How Biogen Is Dealing With Discontinued Alzheimer’s Trial
Biogen shares made a slight gain early on Monday after the firm made an SEC filing indicating that it will be buying back a sizable amount of stock.
Is Neurotrope the Default Alzheimer’s Winner After Biogen’s Implosion?
Neurotrope Inc. (NASDAQ: NTRP) may be a winner by default in the battle against Alzheimer’s disease after shares of Biogen Inc. (NASDAQ: BIIB | BIIB Price Prediction) suffered handily with the announcement that it…